Casdin Partners Master Fund, L.P. - 04 Mar 2024 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role
Director, 10%+ Owner
Signature
Casdin Partners Master Fund, LP By: Casdin Partners GP, LLC, its General Partner By: /s/ Eli Casdin, Managing Member
Issuer symbol
LAB
Transactions as of
04 Mar 2024
Net transactions value
+$646,169
Form type
4
Filing time
06 Mar 2024, 19:20:18 UTC
Previous filing
09 Jan 2024
Next filing
20 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock Purchase $642,500 +250,000 +2.2% $2.57 11,496,525 04 Mar 2024 Direct F1, F2
transaction LAB Common Stock Purchase $3,669 +1,403 +0.01% $2.62 11,497,928 05 Mar 2024 Direct F2
holding LAB Common Stock 103,556 04 Mar 2024 Direct F3
holding LAB Common Stock 2,744,219 04 Mar 2024 See footnoe F4
holding LAB Common Stock 1,200,000 04 Mar 2024 See footnoe F5
holding LAB Common Stock 7,548,000 04 Mar 2024 See footnoe F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.5525 to $2.616. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.
F3 The securities are owned directly by Eli Casdin.
F4 The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
F5 The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Casdin FO1, (ii) the GP, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
F6 The securities are owned directly by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Eli Casdin, who, as a member of the Board of Managers of CMLS Holdings II, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II.

Remarks:

Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer. By virtue of Mr. Casdin's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the Reporting Persons may be deemed directors by deputization of the Issuer. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.